Assure — FY2021 Earnings Presentation
19 slides from Assure's earnings presentation, Mar 14, 2022
Slide 1: 4Q and Full Year 2021 Results
4Q and Full Year 2021 ResultsMarch 14, 2022 NASDAQ: IONM
Slide 2: Cautionary Note regarding Forward-Looking Statements
Cautionary Note regarding Forward‐Looking StatementsThis presentation may contain “forward‐looking statements” within the meaning of applicable securities laws. Forward‐looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "cou
Slide 3: 2021 Overview
2021 Overview Assure Neuromonitoring | 3 Revenue Growth +728% Increased Managed Case Volume +76% Surgeons We Work With +56% Adjusted EBITDA Growth Nasdaq Listing Premier Contracted Supplier Largest Acquisition Launched Remote Neurology Strengthened Balance Sheet
Slide 4: Our Business
Assure Neuromonitoring | 4 Our Business Remote Neurology Services•1‐to‐many model •2,500+ managed cases/year/neurologist* Assure Operations Technologist•1‐to‐1 model •Matches board‐certified technologist with surgeon in the operating room•Each technologist performs ~200 managed cases/year* * See Saf
Slide 5: Remote Neurology Services Opportunity
Assure Neuromonitoring | 5 Remote Neurology ServicesOpportunity•Broad platform potential•Margin improvement with scale•Differentiated offering•Adds organic and M&A targets to funnel•Lowers cost of delivery and improves quality of service•Strong potential for expansion into adjacent markets including
Slide 6: 2022 Drivers for Success
Assure Neuromonitoring | 6 2022 Drivers for Success•Ramping higher margin remote neurology services platform•Awarded three‐year agreement to become sole contracted provider of IONM services for Premier, Inc., the second largest GPO in the U.S.•Organic expansion into new states•Strong potential for a
Slide 7: Remote Neurology Growth Objectives
Remote Neurology Growth Objectives * Based on current run rate 02,12710,00002,0004,0006,000 8,00010,000 12,000202020212022 Forecast*Number of Remote Neurology Managed Cases** Assure Neuromonitoring | 7** See Safe Harbor for definition of Remote Neurology Managed Cases+
Slide 8: Deep Pipeline of Expansion Opportunities
Deep Pipeline of Expansion OpportunitiesExisting Operational Footprint and Targeted States•Expanded into four new states in 2021•Adding density in existing markets•Numerous M&A opportunities•Extending medical device distributor network that has already facilitated expansion into new states•Engaged i
Slide 9: Sole Contracted Supplier of IONM Services for Premier, Inc.
Sole Contracted Supplier of IONM Services for Premier, Inc. Assure Neuromonitoring | 9 Premier is the second largest Group Purchasing Organization in the U.S., uniting an alliance of more than 4,400 hospitals and approximately 225,000 other providers•Assure was awarded a 3‐year agreement to become t
Slide 10: M&A Providing Near-term Benefit and Long-term Upside
M&A Providing Near‐term Benefit and Long‐term Upside Assure Neuromonitoring | 10 2021 Acquisitions•Joint Commission certified IONM provider •Primarily served Texas, but footprint facilitated expansion into Kansas and Missouri•Performed ~5,500 IONM procedures in 2020•Generated ~$5m of incremental cas
Slide 11: 2022 Corporate Objectives
2022 Corporate Objectives •Increase managed cases*by 40%+ in 2022 •Grow organically by expanding into new states and adding density in current markets•Pursue M&A opportunities in highly fragmented industry•Accelerate remote neurology platform•Secure facility‐wide outsourcing agreements •Use data and
Slide 12: Drivers and Trends in Managed Cases
Assure Neuromonitoring | 12 Drivers and Trends in Managed Cases 1,6443,0446,4149,91417,43625,00003,0006,0009,00012,000 15,00018,00021,000 24,000 27,000 Number of Managed Cases*+* See Safe Harbor for definition of Managed Cases All operations in Colorado Operational footprint expands to additional st
Slide 13: 2021 Financial Highlights
2021 Financial Highlights 17,4369,91405,00010,000 15,000 20,000 2021 2020Managed Cases* $29.2$3.5$0$5$10 $15$20$25 $30 2021 2020Revenue $1.1($14.4)($20.0)($15.0)($10.0)($5.0)$0.0$5.0 2021 2020Adj. EBITDA**($m)($m)Assure Neuromonitoring | 13** See reconciliations of non‐GAAP results in the Appendix a
Slide 14: 4Q'21 Financial Highlights
4Q’21 Financial Highlights 5,4853,05701,000 2,000 3,0004,0005,000 6,000 4Q'21 4Q'20Managed Cases* $9.7$6.0$0$4$8$12 4Q'21 4Q'20Revenue $1.4$0.8$0.0$0.2 $0.4 $0.6 $0.8 $1.0 $1.2 $1.4 $1.6 4Q'21 4Q'20Adj. EBITDA**($m)($m)Assure Neuromonitoring | 14** See reconciliations of non‐GAAP results in the Appe
Slide 15: Balance Sheet and Cash Flow Supports Growth Objectives
Balance Sheet and Cash Flow Supports Growth ObjectivesCapitalization •Strengthened financial position: –$5.2m institutional investor‐led private placement + mgmt. and board participation (Nov ‘21)–$11m credit facility secured with Centurion (Jun ‘21)–$10.5m private placement with Special Situations
Slide 16: Streamlining Financial Reporting
Streamlining Financial ReportingRevenue Components •Technical Revenue –Driven by providing technical IONM services in the operating room•Professional Revenue –Derived from providing remote neurology services for IONM•Other Revenue–Primarily represents management fees we receive by performing operati
Slide 17: Q&A
Q&AAssure Holdings7887 E. Belleview Ave., Suite 500, Englewood, CO(720) 617‐2526www.assureneuromonitoring.com Company ContactJohn FarlingerExecutive Chairman and CEOJohn.Farlinger@assureiom.com Investor RelationsScott KozakDirector, Investor and Media RelationsScott.Kozak@assureiom.com Assure Neurom
Slide 18: 4Q'21 Earnings Call - Appendix
4Q’21 Earnings Call ‐AppendixMarch 14, 2022 NASDAQ: IONM
Slide 19: Non-GAAP Financial Measures Reconciliation
Non‐GAAP Financial Measures Reconciliation Assure Neuromonitoring | 19 20212021EBITDA Net Income (loss)(309)$ (325)$ (2,756)$ (15,036)$ Interest expense581 366 1,081 530 Accretion expense 170 163 556 782 Income tax (86) 211 (829) (2,185) Depreciation and amortization 149 245 1,114 1,014 EBITDA 505 6